Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: Review and perspectives
M Heiblig, M Sobh, FE Nicolini - Leukemia Research, 2014 - Elsevier
The treatment of chronic myelogenous leukemia (CML) has been revolutionized by the
introduction of tyrosine kinase inhibitors (TKI), however, with the exception of ponatinib …
introduction of tyrosine kinase inhibitors (TKI), however, with the exception of ponatinib …
Role of interferon (IFN) α in “Cocktails” for the generation of (Leukemia-derived) dendritic cells (DCleu) from blasts in blood from patients (pts) with acute myeloid …
AH Lopez, D Deen, Z Fischer, A Rabe… - Journal of …, 2019 - journals.lww.com
Strategies to stabilize remissions by specific elimination of residual acute myeloid leukemia
(AML) blasts are needed. Leukemia-derived dendritic cell (DC leu/DC) generated from …
(AML) blasts are needed. Leukemia-derived dendritic cell (DC leu/DC) generated from …
[HTML][HTML] STING-cytosolic DNA sensing: the backbone for an effective tumor radiation therapy
Y Liang, H Peng - Annals of translational medicine, 2016 - ncbi.nlm.nih.gov
Local irradiation has been broadly used in the treatment of primary and metastatic tumors. It
is commonly believed that treatment effect of radiation is based on a direct killing of cancer …
is commonly believed that treatment effect of radiation is based on a direct killing of cancer …
Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 study
H Flygt, S Söderlund, J Stentoft… - European journal of …, 2021 - Wiley Online Library
Objectives Treatment‐free remission (TFR) has emerged as a treatment goal in chronic
myeloid leukemia in the chronic phase (CML‐CP). Attempts to increase proportion of …
myeloid leukemia in the chronic phase (CML‐CP). Attempts to increase proportion of …
Inhibition of euchromatic histone methyltransferase 1 and 2 sensitizes chronic myeloid leukemia cells to interferon treatment
Background H3K9 methylation is one of the essential histone post-translational
modifications for heterochromatin formation and transcriptional repression. Recently, several …
modifications for heterochromatin formation and transcriptional repression. Recently, several …
Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy
HF Robertson, D Milojkovic, N Butt… - British Journal of …, 2024 - Wiley Online Library
Diagnosing chronic myeloid leukaemia (CML) during pregnancy is rare. Tyrosine kinase
inhibitors (TKIs) have traditionally been contraindicated owing to their teratogenicity …
inhibitors (TKIs) have traditionally been contraindicated owing to their teratogenicity …
[HTML][HTML] Considerations for successful treatment-free remission in chronic myeloid leukemia
SL Goldberg, M Savona, MJ Mauro - Clinical Lymphoma Myeloma and …, 2018 - Elsevier
BCR-ABL1 tyrosine kinase inhibitors have dramatically improved outcomes for patients with
chronic myeloid leukemia, and current studies are investigating whether some patients may …
chronic myeloid leukemia, and current studies are investigating whether some patients may …
Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib
L Legros, J Guilhot, S Huault, FX Mahon… - Leukemia research, 2014 - Elsevier
In chronic myeloid leukemia (CML), evidence is supporting the role of VEGF in growth, and
survival of leukemia cells. The evaluation of plasma VEGF levels in 403 CML patients …
survival of leukemia cells. The evaluation of plasma VEGF levels in 403 CML patients …
Recombinant Production of Therapeutic Proteins
PS Slathia, Sagrika, E Sharma, IA Khan… - Protein-based …, 2023 - Springer
Therapeutic proteins are gaining importance in disease therapy because of their specificity,
efficiency, safety, and reduced side effects. With the dawn of recombinant DNA technology …
efficiency, safety, and reduced side effects. With the dawn of recombinant DNA technology …